📰 Optune Lua News
Page 7 - Optune Lua News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Optune Lua. Real-time updates on events, politics, business and more.
August 9, 2023
NovoCure (NASDAQ:NVCR – Get Free Report) and Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk. Volatility and Risk NovoCure has a beta of 0.6, […]
August 8, 2023
SVB Leerink began coverage on shares of NovoCure (NASDAQ:NVCR – Free Report) in a report published on Friday, Benzinga reports. The brokerage issued an outperform rating and a $51.00 price objective on the medical equipment provider’s stock. A number of other equities analysts also recently issued reports on the stock. Piper Sandler decreased their price […]
August 8, 2023
NovoCure Limited (NASDAQ:NVCR – Get Free Report)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $26.92, but opened at $28.09. NovoCure shares last traded at $27.24, with a volume of 175,908 shares. Wall Street Analyst Weigh In NVCR has been the topic of a number of […]
August 8, 2023
SVB Leerink initiated coverage on shares of NovoCure (NASDAQ:NVCR – Free Report) in a report released on Friday, Benzinga reports. The firm issued an outperform rating and a $51.00 price target on the medical equipment provider’s stock. Several other research firms have also recently issued reports on NVCR. HC Wainwright cut their price objective on […]
August 7, 2023
NovoCure (NASDAQ:NVCR – Get Free Report) and Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitability. Risk and Volatility NovoCure has a beta of 0.6, […]
August 5, 2023
SVB Leerink assumed coverage on shares of NovoCure (NASDAQ:NVCR – Free Report) in a research report sent to investors on Friday morning, Benzinga reports. The brokerage issued an outperform rating and a $51.00 target price on the medical equipment provider’s stock. NVCR has been the subject of several other reports. SVB Securities started coverage on […]
August 2, 2023
NovoCure (NASDAQ:NVCR – Get Free Report) and Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings. Profitability This table compares NovoCure and Lucid Diagnostics’ net […]
July 31, 2023
StockNews.com downgraded shares of NovoCure (NASDAQ:NVCR – Free Report) from a hold rating to a sell rating in a research note published on Friday. NVCR has been the subject of several other reports. Piper Sandler cut their price objective on NovoCure from $67.00 to $62.00 in a research note on Wednesday, June 7th. Wells Fargo […]
July 24, 2023
Did you lose money on investments in NovoCure Limited? If so, please visit NovoCure Limited Shareholder Class Action Lawsuit or contact Peter Allocco at 951-2030 or pallocco@bernlieb.com to...
July 21, 2023
Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $39.02 and last traded at $39.15, with a volume of 549570 shares changing hands. The stock had previously closed at $39.62. Analyst Upgrades and Downgrades A number of research […]